SPRY

ARS Pharmaceuticals, Inc.

SPRY · CIK 1671858 · Annual (10-K) · Last 4 years

Financial Trends

Revenue$89M
20212024
Net Income$8M
20212024
Operating CF$14M
20212024
Free Cash Flow$13M
20212024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue$0.1B$0.0B$0.0B—
Cost of Revenue$0.0B———
Gross Profit————
R&D Expense$0.0B$0.0B$0.0B$0.1B
SG&A Expense$0.1B$0.0B——
Operating Income$-0.0B$-0.1B$-0.0B$-0.1B
Net Income$0.0B$-0.1B$-0.0B$-0.1B
EPS (Basic)$0.08$-0.57$-0.87—
EPS (Diluted)$0.08$-0.57$-0.87—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.4B$0.2B$0.3B$0.3B
Current Assets$0.3B$0.2B$0.3B$0.3B
Cash & Equivalents$0.1B$0.1B$0.2B$0.3B
Total Liabilities$0.1B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.3B$0.2B$0.3B$0.3B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$0.0B$-0.1B$-0.0B$-0.1B
Investing Cash Flow$-0.1B$-0.1B$-0.0B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.2B$0.0B
← Companies